US-based molecular diagnostics company Myriad Genetics has agreed to acquire informatics-based precision medicine company Assurex Health for $225m.

The potential transaction will be funded by Myriad through cash on hand and debt. An additional $185m will be paid based on performance-based milestone achievements.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Subject to customary closing conditions and regulatory approvals, the transaction is expected to be completed at the beginning of next year.

"It facilitates a personalised treatment plan which result in a faster response and remission for patients."

The transaction will allow Myriad access to Assurex’s GeneSight test.

The GeneSight test is a clinically proven, genetic-based decision support testing tool which analyses the patient’s genes and advises the physicians to prescribe the appropriate medicine.

It facilitates a personalised treatment plan which result in a faster response and remission for patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The GeneSight test will be complemented by Myriad’s myPath Bipolar which is being developed as a differential diagnosis product for major depressive disorder and bipolar disorder.

Myriad is intending to use the psychiatry call point to market the GeneSight test.

Myriad Genetics president and CEO Mark Capone said: "Assurex provides Myriad access to GeneSight one of the fastest growing new diagnostic tests ever in a multi-billion dollar global market and builds upon Myriad's commitment to expand into neuroscience, positioning us for long-term growth.

"Importantly, this acquisition provides an experienced commercial organisation in the neuroscience market that we believe will be one of the highest growth areas for personalised medicine and completes our infrastructure expansion consistent with our four-in-six strategy."

Myriad is being assisted by JP Morgan Securities as the financial advisor and Mintz Levin Cohn Ferris Glovsky and Popeo PC as the legal counsel.

Assurex Health has been advised by Goldman Sachs and Leerink Partners and Latham & Watkins and Thompson-Hine have served as its legal counsel.